258 related articles for article (PubMed ID: 23229369)
1. Stent restenosis and thrombosis: etiology, treatment, and outcomes.
van Buuren F; Dahm JB; Horskotte D
Minerva Med; 2012 Dec; 103(6):503-11. PubMed ID: 23229369
[TBL] [Abstract][Full Text] [Related]
2. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
[TBL] [Abstract][Full Text] [Related]
3. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
[TBL] [Abstract][Full Text] [Related]
4. Stent choice in primary percutaneous coronary intervention: drug-eluting stents or bare metal stents?
Valgimigli M; Airoldi F; Zimarino M
J Cardiovasc Med (Hagerstown); 2009 Oct; 10 Suppl 1():S17-26. PubMed ID: 19851216
[TBL] [Abstract][Full Text] [Related]
5. Coating bioabsorption and chronic bare metal scaffolding versus fully bioabsorbable stent.
Waksman R; Pakala R
EuroIntervention; 2009 Dec; 5 Suppl F():F36-42. PubMed ID: 22100674
[TBL] [Abstract][Full Text] [Related]
6. Emerging drugs for coronary restenosis: the role of systemic oral agents the in stent era.
Rodriguez AE
Expert Opin Emerg Drugs; 2009 Dec; 14(4):561-76. PubMed ID: 19712016
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
[TBL] [Abstract][Full Text] [Related]
8. Drug-eluting stent safety.
Slottow TL; Waksman R
Am J Cardiol; 2007 Oct; 100(8B):10M-17M. PubMed ID: 17950827
[TBL] [Abstract][Full Text] [Related]
9. Assessing the landscape of stent thrombosis: the drug-eluting versus bare-metal stent controversy.
Rizik DG; Klassen KJ
Am J Cardiol; 2008 Nov; 102(9 Suppl):4J-11J. PubMed ID: 18928786
[TBL] [Abstract][Full Text] [Related]
10. [Optimal platelet inhibition after coronary stent implantation. Current status].
Silber S; Hoffmeister HM; Bode C
Herz; 2008 Jun; 33(4):244-53. PubMed ID: 18581073
[TBL] [Abstract][Full Text] [Related]
11. Contemporary treatment of in-stent restenosis and the incidence of recurrent in-stent restenosis in the era of drug-eluting stents.
Ajani AE; Yan BP; Clark DJ; Eccleston D; Walton A; Lew R; Meehan A; Brennan A; Reid C; Duffy SJ;
Heart Lung Circ; 2007 Aug; 16(4):269-73. PubMed ID: 17419097
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome of percutaneous treatment of in-stent restenosis with drug-eluting stents: results from the first phase of the prospective multicentre German DES.DE registry.
Abdel-Wahab M; Nienaber CA; Mostafa AE; Sabin G; Tebbe U; Hochadel M; Senges J; Akin I; Kuck KH; Hamm C; Richardt G;
EuroIntervention; 2011 Jun; 7(2):201-8. PubMed ID: 21646062
[TBL] [Abstract][Full Text] [Related]
13. [Drug-eluting stent-associated thrombosis: clinical relevance of impaired vessel-wall healing].
Koziński M; Sukiennik A; Sinkiewicz W; Kochman W; Kubica J
Postepy Hig Med Dosw (Online); 2008 May; 62():185-205. PubMed ID: 18464681
[TBL] [Abstract][Full Text] [Related]
14. Late and very late thrombosis of drug-eluting stents: evolving concepts and perspectives.
Jaffe R; Strauss BH
J Am Coll Cardiol; 2007 Jul; 50(2):119-27. PubMed ID: 17616295
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes in patients undergoing percutaneous coronary intervention with drug-eluting stents.
Rossini R; Musumeci G; Aprile A; Valsecchi O
Expert Rev Pharmacoecon Outcomes Res; 2010 Feb; 10(1):49-61. PubMed ID: 20121564
[TBL] [Abstract][Full Text] [Related]
16. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials.
De Luca G; Dirksen MT; Spaulding C; Kelbaek H; Schalij M; Thuesen L; van der Hoeven B; Vink MA; Kaiser C; Musto C; Chechi T; Spaziani G; Díaz de la Llera LS; Pasceri V; Di Lorenzo E; Violini R; Cortese G; Suryapranata H; Stone GW;
Arch Intern Med; 2012 Apr; 172(8):611-21; discussion 621-2. PubMed ID: 22529227
[TBL] [Abstract][Full Text] [Related]
17. [The bioresorbable coronary stent: a revolution].
Koegler F; De Benedetti E
Rev Med Suisse; 2013 Apr; 9(381):775-8. PubMed ID: 23659156
[TBL] [Abstract][Full Text] [Related]
18. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications.
Lüscher TF; Steffel J; Eberli FR; Joner M; Nakazawa G; Tanner FC; Virmani R
Circulation; 2007 Feb; 115(8):1051-8. PubMed ID: 17325255
[TBL] [Abstract][Full Text] [Related]
19. Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives.
Ducrocq G; Serebruany V; Tanguay JF
Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):939-53. PubMed ID: 17867923
[TBL] [Abstract][Full Text] [Related]
20. Antiplatelet therapy following drug-eluting stent implantation: new clinical data and recommendations.
Paradis JM; Ducrocq G; Tanguay JF
Minerva Cardioangiol; 2008 Feb; 56(1):139-54. PubMed ID: 18432176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
